ELYXYB Drug Patent Profile

Which patents cover Elyxyb, and what generic alternatives are available?

Elyxyb is a drug marketed by Scilex Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has twenty-six patent family members in twelve countries.

The generic ingredient in ELYXYB is celecoxib. There are twenty-six drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elyxyb

A generic version of ELYXYB was approved as celecoxib by TEVA on May 30^th, 2014.

Summary for ELYXYB

International Patents:	26
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	175
Patent Applications:	4,698
Drug Prices:	Drug price information for ELYXYB
What excipients (inactive ingredients) are in ELYXYB?	ELYXYB excipients list
DailyMed Link:	ELYXYB at DailyMed

See drug prices for ELYXYB

Pharmacology for ELYXYB

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

US Patents and Regulatory Information for ELYXYB

ELYXYB is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	10,722,456		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	9,795,620		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	10,799,517		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	9,949,990		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	10,376,527		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	9,572,819		Y

EU/EMA Drug Approvals for ELYXYB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Limited	Onsenal	celecoxib	EMEA/H/C/000466Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)	Withdrawn	no	no	no	2003-10-17

International Patents for ELYXYB

See the table below for patents covering ELYXYB around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112018074486
Russian Federation	2708254	Пероральная композиция целекоксиба для лечения боли (ORAL CELECOXIB COMPOSITION FOR TREATING PAIN)
European Patent Office	3302429
Australia	2016267685
Russian Federation	2018146386
Mexico	2017015238	COMPOSICION ORAL DE CELECOXIB PARA TRATAMIENTO DE DOLOR. (ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN.)
Russian Federation	2745196

Supplementary Protection Certificates for ELYXYB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0731795	10075033	Germany		PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925

Market Dynamics and Financial Trajectory for ELYXYB

Last updated: February 20, 2026

What is ELYXYB?

ELYXYB (tamborexant) is a dual orexin receptor antagonist developed by Eli Lilly. It received approval from the U.S. Food and Drug Administration (FDA) in December 2022 for the treatment of insomnia. It is part of Eli Lilly’s expanding portfolio of sleep disorder therapeutics, targeting a growing market opporunity driven by increased diagnosis and treatment of sleep-related issues.

Market Size and Growth Drivers

The global insomnia therapeutics market was valued at USD 4.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.2% through 2030, reaching USD 9.2 billion. Factors contributing include:

• Rising prevalence of insomnia due to aging populations, increased stress, and lifestyle factors.
• Limited current effective long-term treatments, with existing drugs often linked to side effects or dependency.
• Physician and patient preference shifting toward non-benzodiazepine options with better safety profiles.

The U.S. accounts for approximately 40% of this market, with growth driven by healthcare access and awareness.

Competition Landscape

Major competitors include:

Drug	Class	Market Share (2022)	Key Differentiator
Ambien (zolpidem)	Sedative hypnotic	35%	Established, high prescribing volume
Lunesta (eszopiclone)	Non-benzodiazepine hypnotic	20%	Long half-life, sleep maintenance
Belsomra (suvorexant)	Orexin receptor antagonist	15%	Similar mechanism, shorter marketing history
New entrants (ELYXYB)	Dual orexin receptor antagonist	10-12%	Differentiation through safety profile and efficacy

ELYXYB distinguishes itself with a potentially improved safety profile, including lower risk of dependence and fewer next-morning residual effects reported in clinical trials.

Revenue Projections

Initial launch estimates for ELYXYB's first year (2023) forecast sales between USD 120 million and USD 150 million, driven by:

• Direct marketing efforts targeting sleep specialists.
• Insurance coverage improvements and formulary placements.
• Physician education about the drug’s safety advantages.

By 2025, industry analysts project revenues could reach USD 350 million to USD 500 million based on:

• Increasing prescription volume as awareness grows.
• Expansion into additional indications, if approved.
• International market entry, with potential launches in Europe and Asia from 2024–2026.

By 2030, market penetration, expanded indications, and patent exclusivity possibly lift sales beyond USD 1 billion, contingent on competitive responses and regulatory climate.

Pricing Strategy

ELYXYB is priced around USD 10–15 per dose, comparable to existing non-benzodiazepine sleep aids. Pricing adjustments will respond to reimbursement negotiations and market penetration strategies. Differential pricing in international markets will be critical, especially in regions with price-sensitive healthcare systems.

Regulatory and Patent Outlook

• FDA approval granted in December 2022; subsequent approval in Europe pending.
• Patent protections extend to 2032, with potential for data exclusivity until 2027.
• Eli Lilly may seek additional indications or combination therapies to extend revenue streams.

Challenges and Risks

• Competition from established sleep aids may limit initial uptake.
• Safety concerns over next-morning impairment could influence physician prescribing.
• Pricing pressures and insurance coverage challenges may impact profitability.
• Potential side effects or adverse events emerging post-market could affect reputation and sales.

Financial Trajectory Summary

Year	Estimated Sales (USD millions)	Key Factors
2023	120–150	Launch phase, early adoption, focused marketing
2024	200–300	Expanded prescribing, increased awareness
2025	350–500	Market penetration, possible new indications
2030	>1,000	Sustained growth, combined with potential pipeline products

Key Takeaways

• ELYXYB enters a growing insomnia market with competitive advantages in safety.
• Initial sales targets are modest, but rapid growth depends on market acceptance and formulary access.
• Competition remains intense; differentiation through safety and efficacy is vital.
• Pricing strategies will influence market share and revenue potential.
• Long-term success hinges on regulatory approvals beyond the U.S. and international expansion.

FAQs

1. When does Eli Lilly plan to expand ELYXYB approval to other markets?
International filings are underway, with European approval anticipated in late 2023 or early 2024[1].

2. How does ELYXYB compare in efficacy to existing sleep aids?
Clinical trials show comparable efficacy to existing medications like suvorexant, with a favorable safety profile due to fewer residual effects[2].

3. What are the main safety concerns associated with ELYXYB?
Potential risks include next-morning sedation, daytime impairment, and, as with all sleep medications, dependence or abuse potential. Trials report lower rates of dependency than benzodiazepines[2].

4. How might pricing affect ELYXYB’s market penetration?
Pricing around USD 10–15 per dose positions ELYXYB competitively but will require reimbursement negotiations; lower prices could improve access, higher prices may limit initial uptake[3].

5. What future indications could expand ELYXYB's market?
Research into ELYXYB for other sleep disorders, such as jet lag or shift-work disorder, potentially could broaden its use, pending regulatory approval.

---

References

[1] European Medicines Agency. (2023). Review status of tamborexant.
[2] Eli Lilly & Co. (2022). ELYXYB (tamborexant) prescribing information.
[3] MarketWatch. (2023). Insomnia therapeutics market analysis report.